A Phase 3 clinical trial, ARAMIS, evaluating Bayer’s (OTCPK:BAYRY)
darolutamide plus androgen deprivation therapy (ADT) in men with
non-metastatic castration-resistant prostate cancer demonstrated a
statistically significant improvement in overall survival (OS) compared to placebo plus ADT, a key secondary endpoint.
Previously published data showed that darolutamide
+ ADT met the primary endpoint of metastasis-free survival compared to
placebo + ADT.
Detailed results will be presented at a future medical conference.
Darolutamide, branded as Nubeqa, is currently approved in the U.S., Japan and Brazil. Filings in the EU and other regions are in process or planned.
https://seekingalpha.com/news/3536246-bayers-darolutamide-extends-survival-in-late-state-prostate-cancer-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.